Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

New research has found that the main component of cannabis, delta-9-tetrahydrocannabinol (THC), leads to people’s attention being more drawn to other cannabis stimuli when using the drug.

Cannabis plant © Shutterstock

Scientists from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London and the University of Oxford has found that the main component of cannabis, delta-9-tetrahydrocannabinol (THC), leads to people’s attention being more drawn to other cannabis stimuli when using the drug, which researchers suggest could underpin the cognitive mechanisms behind cannabis use disorder (CUD).

The research, published in Addiction, also found that levels of cannabidiol (CBD) typically found in cannabis had no modulating effects on the participants, despite many users believing this to be the case.

Following these findings, it is important for people who use cannabis to reflect on their cannabis use to recognise behaviour that could lead to addiction."

Over the course of four sessions, researchers asked 46 infrequent cannabis users (using cannabis less than once a week) to inhale a cannabis vapour containing 10mg of THC, and either 0, 10, 20, or 30mg of CBD. They were then given a task designed to measure what they focused on more when given the choice between options of images (cannabis stimuli vs neutral and food stimuli vs neutral). Researchers found that the acute inhalation of THC resulted in people being more drawn to cannabis-related cues.

Researchers also wanted to establish if the CBD content of the vapour had any effect on the results. Previous research has suggested that high doses of CBD (400-800mg) can reduce cannabis use in individuals with CUD.

However, researchers in this study found that CBD, when delivered at the levels typically found in available products, had no effect.

Professor Philip McGuire from the University of Oxford, the study’s joint senior author, said:

“While THC did not increase participants’ overall liking of cannabis, it increased their sensitivity to cannabis-related stimuli. This suggests that exposure to THC, even when infrequent, may increase the risk of a cannabis use disorder.”

Dr Amir Englund, the study’s joint lead author from King’s IoPPN said: “Cannabis addiction has no one single cause but is rather caused by an interplay of various risk factors when combined with prolonged frequent use.

Our study shows that people with no history of addiction display similar cognitive mechanisms we see in people who have CUD when they are intoxicated. A better understanding of how THC induces these changes can lead to new treatments and measures that prevent CUD.”

Dr Dominic Oliver, the study’s joint lead author from the University of Oxford said:

"Following these findings, it is important for people who use cannabis to reflect on their cannabis use to recognise behaviour that could lead to addiction. We would now want to explore these behaviours in people using cannabis infrequently and frequently, as well as exploring the effects of different doses of THC using both inhaled and oral routes of administration."

This study was fully funded by a research grant from the UK Research and Innovation Medical Research Council.

 

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.